Form 8-K - Current report:
SEC Accession No. 0001193125-24-262641
Filing Date
2024-11-20
Accepted
2024-11-20 17:21:01
Documents
13
Period of Report
2024-11-20
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d902118d8k.htm   iXBRL 8-K 35168
  Complete submission text file 0001193125-24-262641.txt   160729

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kura-20241120.xsd EX-101.SCH 2866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kura-20241120_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kura-20241120_pre.xml EX-101.PRE 11272
15 EXTRACTED XBRL INSTANCE DOCUMENT d902118d8k_htm.xml XML 3639
Mailing Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130
Business Address 12730 HIGH BLUFF DRIVE, SUITE 400 SAN DIEGO CA 92130 (858) 500-8800
Kura Oncology, Inc. (Filer) CIK: 0001422143 (see all company filings)

EIN.: 611547851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37620 | Film No.: 241481385
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)